Exparel 266 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FC1EH
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,106
Award facts
- Contract value 100% obligated
- $25,106.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $25,106.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The award, issued on November 12, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, indicating that DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's recently awarded single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.9 billion ceiling value and extended through December 31, 2036.
DMS Pharmaceutical Group's selection reflects its established capability to supply specialized pharmaceutical products to Department of Defense medical facilities. EXPAREL, a liposomal bupivacaine product, represents the type of specialty surgical pharmaceutical that the company routinely delivers through its comprehensive federal distribution network. As a prime vendor contractor under the PPV-G GEN V program—a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for military healthcare operations—DMS Pharmaceutical Group is positioned as a critical supplier capable of fulfilling diverse and specialized pharmaceutical requirements across the global Department of Defense medical system, with demonstrated performance supporting routine and emergency medical supply needs.
Quick answers
Who was awarded contract SPE2DB26FC1EH?
SPE2DB26FC1EH was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DB26FC1EH worth?
The government has obligated $25,106 on SPE2DB26FC1EH.
Is contract SPE2DB26FC1EH an order under another contract?
Yes. SPE2DB26FC1EH is a delivery order under SPE2DB20D9766, an indefinite delivery contract.
Was contract SPE2DB26FC1EH competed?
The extent of competition for SPE2DB26FC1EH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award